Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.

Dinkelspiel, HE, Champer, M, Hou, J, Tergas, A, Burke, WM, Huang, Y, Neugut, AI, Ananth, CV, Hershman, DL, Wright, JD. Long-term mortality among women with epithelial ovarian cancer. Gynecologic Oncology. 2015; 138: 421-428 [OpenAIRE] [PubMed]

Sopik, V, Iqbal, J, Rosen, B, Narod, SA. Why have ovarian cancer mortality rates declined? Part II. Case-fatality. Gynecologic Oncology. 2015; 138: 750-756 [PubMed]

Johnatty, SE, Tyrer, JP, Kar, S, Beesley, J, Lu, Y, Gao, B, Fasching, PA, Hein, A, Ekici, AB, Beckmann, MW, Lambrechts, D, Van Nieuwenhuysen, E, Vergote, I. Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clin Cancer Res. 2015; 21: 5264-5276 [OpenAIRE] [PubMed]

Mifsud, B, Tavares-Cadete, F, Young, AN, Sugar, R, Schoenfelder, S, Ferreira, L, Wingett, SW, Andrews, S, Grey, W, Ewels, PA, Herman, B, Happe, S, Higgs, A. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat Genet. 2015; 47: 598-606 [OpenAIRE] [PubMed]

Li, G, Ruan, X, Auerbach, RK, Sandhu, KS, Zheng, M, Wang, P, Poh, HM, Goh, Y, Lim, J, Zhang, J, Sim, HS, Peh, SQ, Mulawadi, FH. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell. 2012; 148: 84-98 [OpenAIRE] [PubMed]

Ardlie, KG, Deluca, DS, Segrè, AV, Sullivan, TJ, Young, TR, Gelfand, ET, Trowbridge, CA, Maller, JB, Tukiainen, T, Lek, M, Ward, LD, Kheradpour, P, Iriarte, B. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science. 2015; 348: 648-660 [OpenAIRE] [PubMed]

Hou, C, Dale, R, Dean, A. Cell type specificity of chromatin organization mediated by CTCF and cohesin. Proc Natl Acad Sci U S A. 2010; 107: 3651-3656 [OpenAIRE] [PubMed]

Heinz, S, Romanoski, CE, Benner, C, Glass, CK. The selection and function of cell type-specific enhancers. Nat Rev Mol Cell Biol. 2015; 16: 144-154 [OpenAIRE] [PubMed]

Hnisz, D, Abraham, BJ, Lee, TI, Lau, A, Saint-André, V, Sigova, AA, Hoke, HA, Young, RA. Super-enhancers in the control of cell identity and disease. Cell. 2013; 155: 934-947 [OpenAIRE] [PubMed]

Ørom, UA, Shiekhattar, R. Long non-coding RNAs and enhancers. Curr Opin Genet Dev. 2011; 21: 194-198 [OpenAIRE] [PubMed]

Li, S, Weidenfeld, J, Morrisey, EE. Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol Cell Biol. 2004; 24: 809-822 [OpenAIRE] [PubMed]

Choi, EJ, Seo, EJ, Kim, DK, Lee, SI, Kwon, YW, Jang, IH, Kim, KH, Suh, DS, Kim, JH. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget. 2016; 7: 3506-3519 [OpenAIRE] [PubMed] [DOI]

Gyorffy, B, Lanczky, A, Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19: 197-208 [OpenAIRE] [PubMed]

Amos, CI, Dennis, J, Wang, Z, Byun, J, Schumacher, FR, Gayther, SA, Casey, G, Hunter, DJ, Sellers, TA, Gruber, SB, Dunning, AM, Michailidou, K, Fachal, L. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev. 2017; 26: 126-135 [OpenAIRE] [PubMed]

Breitbart, RE, Liang, CS, Smoot, LB, Laheru, DA, Mahdavi, V, Nadal-Ginard, B. A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage. Development. 1993; 118: 1095-1106 [PubMed]